Shilpa Gupta, MD, FASCO (@shilpaonc) ranks #7 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 50 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: VOLGA, TALAPRO-3, EV-302. CMS Open Payments lists $82,838 in 2025 general payments.
At a Glance
- 13 posts naming a trial in 2026
- 9 trials discussed by name
- GU Cancer: US #7, Global #11 · 50 physicians engaged
- Leading physician voice: #2 of 57 physicians on VOLGA
- Presented at ASCO 2026 in 2026
- CMS Open Payments lists $82,838 in 2025 general payments.
This Month
What Shilpa Gupta, MD, FASCO has posted in the last 30 days. Updated November 10, 2026.
Huge congratulations @neerajaiims & entire TALAPRO-3 team on the FDA approval of talazoparib-enza ! 🎉👏 A major milestone for precision medicine in mHSPC! @AzadOncology @quimmateo @PCFnews @OncoAlert @montypal @DrChoueiri @PGrivasMDPhD @Uromigos @ChrisSweens1 https://t.co/DOu1QqFrzw
The #ESMO26 Presidential Symposium is about to begin! 🔥 Super excited to hear the highly anticipated results of the VOLGA trial, presented by the the only and only @tompowles1! @myESMO @apolo_andrea @Uromigos @brian_rini @OncoAlert @LosUromigos @uromigosjapan @MichvdHeijden
Kudos @tompowles1 on a fantastic #VOLGA presidential @ #ESMO26 👏 Less is More! • Cis-inelig MIBC, 25% were cis refusers • D+EV x3 → RC → adj D x9 (NO adj EV) • EFS HR 0.51 • OS HR 0.58 • pCR 45 vs 10% • G3-4 TRAE 30%, • neuropathy only 18% • imAEs 33% (G3-4 11%) • GHS/QoL maintained post-RC • Treme ↑tox (G3-4 42%, 5 deaths), NO OS gain. My take: it's not just about chasing bigger numbers. Tox matters too, especially when OS is achieved. Need to discuss the pros and cons with patients. Less PN and skin tox, and fewer G3+ immune AEs than more cycles and that's a win for patients ! 🙌 @Uromigos @OncoAlert @brian_rini @LosUromigos @drenriquegrande
#ESMO26 Very thoughtful and balanced discussion of VOLGA trial by @MichvdHeijden , putting EV-D in perspective with EV-303/B15 on efficacy & safety. Adding treme = more tox, no efficacy/OS gain. Less is more! Takeaway for next steps: response-adapted adjuvant therapy? @myESMO @tompowles1 @brian_rini @Uromigos
Bravo @AndreaNecchi on a superb presentation of ENERGIZE trial at @myESMO #ESMO26 ! 👏 Ph3, n=653 cis-eligible MIBC: neoadj GC + nivo → adj nivo vs GC alone. Median f/u 54.5 mo. 🔹 pCR 39.1% vs 29.6%: not dig 🔹 EFS HR 0.94: co-primaries not met 🔹 OS HR 0.88 👉Negative trial, but the ctDNA data are a key message: detectable ctDNA at baseline and after NAC strongly prognostic for worse EFS & OS. Selecting patients by ctDNA, rather than adding IO for all, is where the field is heading! Great to see this build on our Ph2 BLASST-1. Despite the negative result, it's very practice-informing. Proud to be a part of this effort! @CleClinicMD @caseccc @CleClinicUro @sonpavde @MattGalsky @MichvdHeijden @Uromigos @Annals_Oncology @tompowles1
Who Amplifies Shilpa Gupta, MD, FASCO
Physicians who reposted Shilpa Gupta, MD, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #7 | #11 | 50 | 105 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Shilpa Gupta, MD, FASCO presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASCO 2026 · Presentation (Abstract 4514)MAIN-CAV: Maintenance cabozantinib + avelumab vs avelumab alone after 1L platinum-based chemotherapy in locally advanced/metastatic urothelial cancerSource: @nataliagandur on X ↗
What Colleagues Are Saying About Shilpa Gupta, MD, FASCO
2026 posts by fellow physicians that mention @shilpaonc, quoted word for word.
6-Abstract 4514: MAIN-CAV Dr. @shilpaonc will present this phase 3 trial at #ASCO26, evaluating cabozantinib + avelumab vs avelumab alone as maintenance therapy in locally advanced/metastatic UC. @DrRosenbergMSK @ASCO @OncoAlert https://t.co/v6SBe69iAm
#ASCO26 GU Oncology Spotlight 🚨 🔬 Abstract 4514 | MAIN-CAV Maintenance cabozantinib + avelumab vs avelumab alone after 1L platinum-based chemotherapy in locally advanced/metastatic urothelial cancer Presented by Shilpa Gupta, MD @shilpaonc @ASCO @OncoAlert 🔵 Clinical question Can we improve on maintenance avelumab by adding cabozantinib after platinum-based chemotherapy in la/mUC? The rationale was strong: ➡️ avelumab maintenance is an established post-platinum standard ➡️ most patients eventually progress ➡️ cabozantinib targets VEGFR/MET/TAM pathways and may modulate an immunosuppressive tumor microenvironment 🟠 What MAIN-CAV showed This phase III trial closed early after only 68 patients were enrolled, following the adoption of EV + pembrolizumab as a new preferred first-line standard. So interpretation is limited. But the signal was clear enough: • Median OS: 24.8 mo with avelumab vs 23.0 mo with cabo + avelumab • HR 1.41; p = 0.186 • Median PFS: 4.6 vs 6.0 mo; p = 0.343 • No statistically significant improvement in OS or PFS 🔴 Toxicity / feasibility The combination added treatment burden: • Grade ≥3 TRAEs: 24.2% with avelumab vs 39.4% with cabo + avelumab • Cabozantinib dose reductions occurred in about two-thirds of patients • No new safety signals, but clearly more management complexity 🧠 My take MAIN-CAV is a useful negative study. It tells us that simply adding a VEGF/MET/TAM inhibitor to avelumab maintenance did not improve outcomes in this underpowered, prematurely closed trial — and did add toxicity. In 2026, the bigger algorithm question is also different: ➡️ What is the role of maintenance strategies after the EV/pembrolizumab shift in 1L la/mUC? For now: ✅ avelumab maintenance remains an important historical benchmark ✅ cabo + avelumab should not be adopted as a maintenance standard ✅ negative trials still matter because they prevent ineffective intensification More treatment is not always better treatment. #ASCO26 #GUOnc #BladderCancer #UrothelialCancer #laMUC #Immunotherapy #Avelumab #Cabozantinib #ClinicalTrials @shilpaonc @MattGalsky @PGrivasMDPhD @tompowles1 @DrRanaMcKay @DrChoueiri @DrYukselUrun @brian_rini @montypal @OncLive @TargetedOnc @CancerNetwrk @ASCOPost @ecancer @VJOncology @curetoday @NEJM @JCO_ASCO
What’s changing in #bladdercancer treatment right now? Join me, @siadaneshmand & @shilpaonc at #ASCO26 as we discuss ICIs, ADCs & combination strategies shaping care across the disease spectrum ➡️ May 30 at 7 PM CDT, Chicago or virtual: https://t.co/csGJnBswkv @PeerView
Trials Shilpa Gupta, MD, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| VOLGA | 5 | #2 of 57 | Oct 24, 2026 |
| TALAPRO-3 | 2 | #5 of 39 | Oct 26, 2026 |
| EV-302 | 2 | #5 of 19 | May 29, 2026 |
| ENERGIZE (CA017-078) | 1 | #5 of 17 | Oct 23, 2026 |
| IMvigor011 | 1 | #11 of 20 | May 16, 2026 |
| SunRISe-2 | 1 | #5 of 5 | Mar 6, 2026 |
| BRCAAway | 1 | #5 of 5 | Feb 27, 2026 |
| PEACE-3 | 1 | #8 of 10 | Feb 27, 2026 |
| PSMAADDITION | 1 | — | Feb 27, 2026 |
Shilpa Gupta, MD, FASCO on VOLGA
The #ESMO26 Presidential Symposium is about to begin! 🔥 Super excited to hear the highly anticipated results of the VOLGA trial, presented by the the only and only @tompowles1! @myESMO @apolo_andrea @Uromigos @brian_rini @OncoAlert @LosUromigos @uromigosjapan @MichvdHeijden
Kudos @tompowles1 on a fantastic #VOLGA presidential @ #ESMO26 👏 Less is More! • Cis-inelig MIBC, 25% were cis refusers • D+EV x3 → RC → adj D x9 (NO adj EV) • EFS HR 0.51 • OS HR 0.58 • pCR 45 vs 10% • G3-4 TRAE 30%, • neuropathy only 18% • imAEs 33% (G3-4 11%) • GHS/QoL maintained post-RC • Treme ↑tox (G3-4 42%, 5 deaths), NO OS gain. My take: it's not just about chasing bigger numbers. Tox matters too, especially when OS is achieved. Need to discuss the pros and cons with patients. Less PN and skin tox, and fewer G3+ immune AEs than more cycles and that's a win for patients ! 🙌 @Uromigos @OncoAlert @brian_rini @LosUromigos @drenriquegrande
#ESMO26 Very thoughtful and balanced discussion of VOLGA trial by @MichvdHeijden , putting EV-D in perspective with EV-303/B15 on efficacy & safety. Adding treme = more tox, no efficacy/OS gain. Less is more! Takeaway for next steps: response-adapted adjuvant therapy? @myESMO @tompowles1 @brian_rini @Uromigos
Shilpa Gupta, MD, FASCO on TALAPRO-3
Huge congratulations @neerajaiims & entire TALAPRO-3 team on the FDA approval of talazoparib-enza ! 🎉👏 A major milestone for precision medicine in mHSPC! @AzadOncology @quimmateo @PCFnews @OncoAlert @montypal @DrChoueiri @PGrivasMDPhD @Uromigos @ChrisSweens1 https://t.co/DOu1QqFrzw
So proud to watch the my dear friend & mentor @neerajaiims present TALAPRO-3 at #ASCO26 with a simultaneous publication in @NEJM today! Tala + enza rPFS (HR 0.48), with 3-year rPFS of 76.6% vs 56.2% in pts with HRR-deficient mHSPC. Kudos to Neeraj and entire TALAPRO-3 team on this new standard! @ASCOPost @DrChoueiri @OncoAlert @Uromigos
Shilpa Gupta, MD, FASCO on EV-302
Looking forward to today’s bladder and kidney cancer oral sessions at #ASCO26. Congratulations to all the presenters! Especially excited to see @tompowles1 present the 3.5-year FU from EV-302 with subsequent Tx & outcomes that will help inform real-world patient care. Looking forward to the discussion by @apolo_andrea on the rapidly evolving era of nectin-4 ADCs shaping bladderca care. 📍Arie Crown Theatre] 🕒 [2.45-5.45 PM CST @uromigosjapan @Uromigos @TresUramigas @brian_rini @ASCOPost @CleClinicMD @OncoAlert @OncBrothers @urotoday @GUOncologyNow
Outstanding discussion by @apolo_andrea of the past, present & future of nectin-4 ADCs in UC #ASCO26 From EV-302 establishing EV+pembro as a transformative 1L therapy in mUC to a growing pipeline of next-generation Nectin-4 ADCs, the field continues to move rapidly. Key unanswered Qs remain: • Dose optimization • Treatment duration • Sequencing strategies • Mechanisms of resistance @tompowles1 @IyerGopa @ASCO
Shilpa Gupta, MD, FASCO on ENERGIZE (CA017-078)
Bravo @AndreaNecchi on a superb presentation of ENERGIZE trial at @myESMO #ESMO26 ! 👏 Ph3, n=653 cis-eligible MIBC: neoadj GC + nivo → adj nivo vs GC alone. Median f/u 54.5 mo. 🔹 pCR 39.1% vs 29.6%: not dig 🔹 EFS HR 0.94: co-primaries not met 🔹 OS HR 0.88 👉Negative trial, but the ctDNA data are a key message: detectable ctDNA at baseline and after NAC strongly prognostic for worse EFS & OS. Selecting patients by ctDNA, rather than adding IO for all, is where the field is heading! Great to see this build on our Ph2 BLASST-1. Despite the negative result, it's very practice-informing. Proud to be a part of this effort! @CleClinicMD @caseccc @CleClinicUro @sonpavde @MattGalsky @MichvdHeijden @Uromigos @Annals_Oncology @tompowles1
Shilpa Gupta, MD, FASCO on IMvigor011
Congrats @tompowles1, IMvigor011 investigators, and @Roche on this important advance of ctDNA guided adjuvant atezolizumab use in MIBC! ctDNA is one of the most promising biomarkers we have, and it’s remarkable to see how the team built upon the lessons learned from the critical negative trial IMvigor010 to help shape a precision medicine path forward in bladder cancer, helping select patients who would benefit from adjuvant IO. @Uromigos @TresUramigas @uromigosjapan @IBCG_BladderCA @urotoday @UroDocAsh @PGrivasMDPhD @montypal @neerajaiims @brian_rini @BladderCancerUS @AndreaNecchi @NateraGenetics
Shilpa Gupta, MD, FASCO on SunRISe-2
Excellent podcast reviewing the innovative SunRISe-2 trial with @AndreaNecchi 1st trial in MIBC with such an experimental arm against CRT. While closed early for futility, experimental arm didn't perform well even without CRT. Lessons learned and what the future holds! @Uromigos @uromigosjapan @TresUramigas @brian_rini @tompowles1
Shilpa Gupta, MD, FASCO on BRCAAway
What a great Day 1 at #ASCOGU26! Meeting friends & colleagues & learning about latest data in #ProstateCancer Key Takeaways 👉PEACE-3: ARPI + radium-223 improves OS in mCRPC 👉BRCAAway: Upfront PARPi + abiraterone > sequential Tx in BRCA mCRPC 👉 PSMAaddition: Early Lu-PSMA maintains QOL 👉ASCENDE-RT: Better control, ↑ GU toxicity Patient selection matters! @OncoAlert @oncodaily @Uromigos @DrYukselUrun
Shilpa Gupta, MD, FASCO on PEACE-3
What a great Day 1 at #ASCOGU26! Meeting friends & colleagues & learning about latest data in #ProstateCancer Key Takeaways 👉PEACE-3: ARPI + radium-223 improves OS in mCRPC 👉BRCAAway: Upfront PARPi + abiraterone > sequential Tx in BRCA mCRPC 👉 PSMAaddition: Early Lu-PSMA maintains QOL 👉ASCENDE-RT: Better control, ↑ GU toxicity Patient selection matters! @OncoAlert @oncodaily @Uromigos @DrYukselUrun
Shilpa Gupta, MD, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
ctDNA is an exciting and important advance but not a replacement for imaging for recurrence post-cystectomy. IMvigor011 highlights an important biologic shedding pattern of ctDNA with nodal disease being missed. CtDNA should be considered complementary, not a replacement for standard imaging. @UroDocAsh @IBCG_BladderCA @ResearchWyatt @carme_mir1
Honored to be in Beijing as a keynote speaker at the 4th Clinical Research UroOnc Conference, hosted by Dr.Jun Gao (PI, DV–toripalimab in 1L mUC; @NEJM 2025). What stood out was the pace and scale of clinical research across GU cancers, especially the rapid progress in ADC–IO combinations in bladder cancer. The depth of innovation and execution in 🇨🇳 is actively reshaping the global clinical trial landscape. Also had the opportunity to tour their new hospital with truly state-of-the-art clinical trials infrastructure. Grateful for the warm hospitality & the chance to make new friends to develop collaborations for advancing progress & helping close gaps in 🌍 access and disparities. @CleClinicMD @brian_rini @tompowles1 @Uromigos
Thanks @crisbergerot for the shoutout! Patient voices matter! @ASCO #ASCO26 Proud to be part of this important PRO work from IMvigor011, the 1st biomarker-based phase 3 trial using ctDNA to guide adjuvant IO in MIBC, with the goal of treating those who would benefit most while sparing unnecessary toxicity, including financial toxicity. @tompowles1 @Uromigos @TresUramigas @uromigosjapan @IBCG_BladderCA @UroDocAsh @montypal @neerajaiims @PGrivasMDPhD @CleClinicMD @CleClinicUro @jamecancerdoc
Important subgroup analyses from the PSMAdditon trial to be presented at #ASCO26 Proud for us @CleClinicMD to be the highest enrolling site in the US for this trial and grateful to all our patients, staff and research personnel who made this trial a success! @caseccc @ChrisWeeMD @AmandaNizamMD @MosheOrnsteinMD @jamecancerdoc @ZEROCancer @PCF_Science
Moments like this remind us why we do what we do! A standing ovation and a pivotal moment not just for a drug, but for years of persistence, science, and hope for our patients. #ASCO26 @ASCO @ASCOPres @aakonc @smitha42 @Uromigos @DrChoueiri @OncoAlert https://t.co/d0wA8801ZZ
Industry Payments
CMS Open Payments · 2025 general payments
$82,838 across 61 payments